Cargando…
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren’s syndrome (SS) and the current availability of various biological agents (anti-TNF-α, IFN- α, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention....
Autores principales: | Meijer, Jiska M., Pijpe, Justin, Bootsma, Hendrika, Vissink, Arjan, Kallenberg, Cees G. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Humana Press Inc
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2071970/ https://www.ncbi.nlm.nih.gov/pubmed/17992596 http://dx.doi.org/10.1007/s12016-007-8005-6 |
Ejemplares similares
-
What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?
por: Kallenberg, Cees GM, et al.
Publicado: (2011) -
Imaging in Primary Sjögren’s Syndrome
por: van Ginkel, Martha S., et al.
Publicado: (2020) -
Current insights into the relationship between the gut microbiome and Sjögren’s syndrome
por: van der Meulen, Taco A., et al.
Publicado: (2020) -
Bcl6 for identification of germinal centres in salivary gland biopsies in primary Sjögren's syndrome
por: Nakshbandi, Uzma, et al.
Publicado: (2020) -
Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model
por: Horvath, Steve, et al.
Publicado: (2012)